171746-21-7

Basic information

• Product Name: AGN 193109
• Synonyms: AGN 193109;4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl]ethynyl]benzoic Acid;CD 3106;4-{[5,5-diMethyl-8-(4-Methylphenyl)-5,6-dihydronaphthalen-2-yl]ethynyl}benzoic acid;AGN 193109 SodiuM Salt;4-((5,5-Dimethyl-8-p-tolyl-5,6-dihydronaphthalen-2-yl)ethynyl)benzoic acid
• CAS NO: 171746-21-7
• Molecular Formula: C28H24O2
• Molecular Weight: 392.496
• Product Categories: Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 171746-21-7.mol

Chemical Properties

• Melting Point: 246-255?C
• Boiling Point: 564.5 °C at 760 mmHg
• Flash Point: 257.1 °C
• Appearance: /
• Density: 1.21 g/cm³
• Vapor Pressure: 1.41E-13mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly, Heated), DMSO (Slightly, Sonicated)
• PKA: 4.08±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: AGN 193109(CAS DataBase Reference)
• NIST Chemistry Reference: AGN 193109(171746-21-7)
• EPA Substance Registry System: AGN 193109(171746-21-7)

Safety Data

• Hazardous Substances Data: 171746-21-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
AGN 193109 is used as a retinoic acid receptor (RAR) antagonist for treating chemotherapy and radiation therapy side effects. By blocking the activity of RARs, it can help alleviate the adverse effects associated with these cancer treatments, improving the quality of life for patients undergoing such therapies.
Used in Cancer Treatment:
AGN 193109 is used as a therapeutic agent for cancer treatment. Its RAR antagonistic properties allow it to interfere with the signaling pathways that contribute to cancer cell growth and proliferation. This can potentially lead to the inhibition of tumor growth and the prevention of cancer progression.
Used in Drug Delivery Systems:
In the field of drug delivery, AGN 193109 can be utilized as a component in the development of novel drug delivery systems. These systems can be designed to improve the bioavailability, targeting, and overall efficacy of the compound, making it a more effective treatment option for various medical conditions, including cancer and side effects of chemotherapy and radiation therapy.

InChI:InChI=1/C28H24O2/c1-19-4-11-22(12-5-19)24-16-17-28(2,3)26-15-10-21(18-25(24)26)7-6-20-8-13-23(14-9-20)27(29)30/h4-5,8-16,18H,17H2,1-3H3,(H,29,30)

Upstream product

• 171568-43-7 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl)ethynyl]benzoate 
• 2979-69-3 3,4-dihydro-4,4-dimethyl-1(2H)-naphthalenone 
• 166978-48-9 7-ethynyl-3,4-dihydro-4,4-dimethylnaphthalen-1-(2H)-one 
• 166978-46-7 7-bromo-4,4-dimethyl-3,4-dihydro-2H-naphthalen-1-one 
• 171568-44-8 ethyl 4-[(5,6-dihydro-5,5-dimethyl-8-(trifluoromethylsulfonyl)oxy-2-naphthalenyl)ethynyl]benzoate 
• 166978-49-0 ethyl 4-[(5,6,7,8-tetrahydro-5,5-dimethyl-8-oxo-2-naphthalenyl)ethynyl]benzoate 
• 166978-47-8 7-(trimethylsilyl)ethynyl-3,4-dihydro-4,4-dimethylnaphthalen-1-(2H)-one 

Relevant articles and documents

SYNTHESIS AND USE OF RETINOID COMPOUNDS HAVING NEGATIVE HORMONE AND/OR ANTAGONIST ACTIVITIES

2,2-Dialkyl-4-aryl-substituted benzopyran and benzothiopyran derivatives of the formula STR1 where the symbols have the meaning described in the specification, have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists.

Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.